Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
ORGANIZATION
Ono President Apologizes to JPMA After 2 Employees Are Indicted for Bribery
Ono Pharmaceutical President Gyo Sagara apologized at a board meeting of the Japan Pharmaceutical Manufacturers Association (JPMA) on February 18 for a scandal involving two of the company’s employees who have been indicted by the Tsu District Public Prosecutor’s Office…
To read the full story
Related Article
- Maker FTC Issues “Warning” to Ono over Onoact Bribery Case
December 16, 2021
- JPMA Suspends Ono’s Membership over Onoact Bribery Case
September 17, 2021
- Probe Panel Urges Ono to Establish Foundation to Handle Scholarship Donations after Bribery Case
August 16, 2021
- Guilty Ruling for Ono Employees Now Final and Binding: Onoact Case
July 15, 2021
- 2 Ono Employees Found Guilty for Onoact Bribery Charges; Scholarship Donation in Spotlight
June 30, 2021
- Jail Terms Sought for 2 Ono Employees over Onoact-Tied Bribery Charges
June 1, 2021
- 2 Ono Employees Admits Bribery Charges over Onoact Prescriptions
May 17, 2021
- Ono Sets Up Investigation Panel on Bribery Issue
February 19, 2021
- Ono Apologizes over Arrest of 2 Employees on Bribery Allegations
January 29, 2021
ORGANIZATION
- JPMA, PhRMA Raise Alarm over Generic Approvals During Patent Extensions
July 17, 2026
- WHO Opens Tokyo Hub to Help Health Systems in Developing Nations
July 16, 2026
- FIRM Unveils Vision 2030 to Bolster Japan’s Regenerative Medicine Industry
July 15, 2026
- FIRM Backs Growth Roadmap, Expects Better Investment Climate
July 10, 2026
- JPMA Sees Honebuto Shifting toward Industry Promotion, Still Against Off-Year Cuts
July 10, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…